CLNN

Clene is a clinical-stage nanotech pharma that, in its own words, has 'no drugs approved for commercial sale,' has 'never been profitable,' and has 'incurred operating losses in each year since inception.' The trivial $200K of FY2025 revenue is dietary-supplement income from its dOrbital subsidiary and a 4Life license — explicitly described as 'small compared to our operating expenses.' So this is not a company you value on sales; the 370.4x P/S is a meaningless artifact. It must be judged as a binary clinical bet on CSN therapeutics for ALS, MS and Parkinson's, and the balance sheet is the dominant fact.

The financials are in distress. Stockholders' equity is NEGATIVE $17.6M (down 98.6% YoY) against $35.7M of liabilities and only $18.1M of total assets — liabilities/equity of -2.03x means the company is balance-sheet insolvent on a book basis, with a $308M accumulated deficit. Cash fell 57.3% to $5.19M while operating cash burn ran -$18.5M for the year (~$4.6M/quarter), implying a runway of roughly one quarter without new capital. Long-term debt is $17.8M, and current liabilities ($10.8M) already exceed current assets ($8.98M) for negative working capital. Even the 'improving' numbers are improving for the wrong reason: the 33.6% narrower net loss and 30.1% lower R&D reflect spending cuts and shrinking scale (revenue itself fell 41.5%), not progress toward viability.